BioCatalyst

ARGX — ARGENX SE catalysts

4 verified catalyst event(s) for ARGENX SE (ticker ARGX). Each is linked to its official source. Verified as of 2026-08-06.

Next verified catalyst

2026-09-01 — A Study to Assess the Efficacy and Safety of Empasiprubart Versus IVIg in Adults With Mult · official source ↗

Upcoming

DateEventCompanyDrugOfficial source & verification
2026-09 (month)
in 26d
ESTIMATED
 READOUT
A Study to Assess the Efficacy and Safety of Empasiprubart Versus IVIg in Adults
Phase 3 · Multifocal Motor Neuropathy (MMN), MMN
 ARGX ARGENX SE Empasiprubart, IVIG (Intravenous Immunog ClinicalTrials.gov ↗
✓ Source-checked 2026-08-06
Sponsor-projected date — can change
2026-09-30
in 2mo
ESTIMATED
 READOUT
A Study of Efgartigimod PH20 SC in Children Between 2 and Less Than 18 Years of
Phase 2/3 · Generalized Myasthenia Gravis
 ARGX ARGENX SE Efgartigimod PH20 SC ClinicalTrials.gov ↗
✓ Source-checked 2026-08-06
Sponsor-projected date — can change
2026-10-01
in 2mo
ESTIMATED
 READOUT
A Phase 3 Study to Evaluate the Safety and Efficacy of Efgartigimod PH20 Subcuta
Phase 3 · Primary Immune Thrombocytopenia
 ARGX ARGENX SE efgartigimod PH20 SC ClinicalTrials.gov ↗
✓ Source-checked 2026-08-06
Sponsor-projected date — can change
2026-11 (month)
in 3mo
ESTIMATED
 READOUT
A Study to Evaluate Safety and Efficacy of Empasiprubart in Adults With Dermatom
Phase 2 · Dermatomyositis, Myositis
 ARGX ARGENX SE Empasiprubart IV ClinicalTrials.gov ↗
✓ Source-checked 2026-08-06
Sponsor-projected date — can change
Disclaimer. Bio Catalyst Calendar is a public-events data calendar. Every date is sourced and linked to an official record (ClinicalTrials.gov, FDA / Federal Register, openFDA). It is scheduling and reference data only — NOT investment advice, a recommendation, or a buy/sell signal. Dates set by sponsors and the FDA can change; always confirm against the linked official source.